| 前收市價 | 2.5000 |
| 開市 | 無 |
| 買盤 | 3.4000 |
| 賣出價 | 4.9000 |
| 拍板 | 17.50 |
| 到期日 | 2024-05-17 |
| 今日波幅 | 2.5000 - 2.5000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 5 |
ZacksRoche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ZacksALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
ZacksNurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
